Form 4: Crinetics Pharmaceuticals Executive James Hassard Reports Stock Transaction
SEC Form 4 Filing
James Hassard, Chief Commercial Officer of Crinetics Pharmaceuticals, reports disposition of shares to cover tax obligations upon vesting of Restricted Stock Units.
Summary
- On March 18, 2024, James Hassard, the Chief Commercial Officer of Crinetics Pharmaceuticals, Inc. (CRNX), disposed of 1,741 shares of common stock.
- The disposition was to cover tax withholding obligations related to the vesting of Restricted Stock Units granted on March 1, 2023.
- The transaction was executed at a price of $38.14 per share.
- Following the transaction, Hassard directly owns 29,259 shares of Crinetics Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations arising from the vesting of stock-based compensation, a common practice in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | Date of Restricted Stock Units grant |
| 03/18/2024 | Date of stock transaction |
| 03/20/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.